Literature DB >> 10855766

Herpes simplex virus: the importance of asymptomatic shedding.

D M Koelle1, A Wald.   

Abstract

Herpes simplex virus (HSV) is frequently shed after infection of the genital or perianal area. HSV shedding, as determined by culture, occurs on about 3% of days for immunocompetent women and men, and more for persons with HIV infection or if measured by polymerase chain reaction (PCR). Most horizontal and vertical transmission of HSV occurs during unrecognized or asymptomatic shedding, and the majority of HSV-2-infected persons are unaware of their infection. Many persons with 'asymptomatic' HSV-2 infection can learn to recognize genital signs and symptoms as recurrences of HSV-2 infection. However, some shedding episodes remain truly asymptomatic even after patient education. Antiviral therapy dramatically reduces asymptomatic shedding, and trials to evaluate its effect on HSV transmission are underway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10855766     DOI: 10.1093/jac/45.suppl_4.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  44 in total

1.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

2.  Diagnosis of genital herpes by real time PCR in routine clinical practice.

Authors:  M Ramaswamy; C McDonald; M Smith; D Thomas; S Maxwell; M Tenant-Flowers; A M Geretti
Journal:  Sex Transm Infect       Date:  2004-10       Impact factor: 3.519

3.  Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1.

Authors:  Felix N Toka; Malgorzata Gierynska; Barry T Rouse
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Genital herpes.

Authors:  A M Geretti
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

5.  Abortive herpes simplex virus infection of nonneuronal cells results in quiescent viral genomes that can reactivate.

Authors:  Efrat M Cohen; Nir Avital; Meir Shamay; Oren Kobiler
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-23       Impact factor: 11.205

6. 

Authors:  A Amor; M Sánchez-Conde
Journal:  Medicine (Madr)       Date:  2009-01-06

7.  Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Authors:  Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.

Authors:  Sri P Vagvala; Lydia G Thebeau; Saydra R Wilson; Lynda A Morrison
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

9.  Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.

Authors:  Bulbulgul Aumakhan; Charlotte A Gaydos; Thomas C Quinn; Chris Beyrer; Lorie Benning; Howard Minkoff; Daniel J Merenstein; Mardge Cohen; Ruth Greenblatt; Marek Nowicki; Kathryn Anastos; Stephen J Gange
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

10.  Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?

Authors:  Paul E Bonnar
Journal:  Mcgill J Med       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.